Trial Profile
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Apr 2023 Interim results (n=34) presented at the 114th Annual Meeting of the American Association for Cancer Research